Market Closed -
OTC Markets
02:35:53 2024-05-14 pm EDT
|
5-day change
|
1st Jan Change
|
0.09
USD
|
+5.97%
|
|
+5.88%
|
-3.85%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
11.14
|
9.108
|
18.43
|
25.42
|
18.31
|
6.943
|
Enterprise Value (EV)
1 |
4.642
|
3.662
|
-29.71
|
-22.22
|
-28.68
|
-40.07
|
P/E ratio
|
1.9
x
|
-9.3
x
|
-7.17
x
|
-10.2
x
|
-12.5
x
|
70.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.61
x
|
44
x
|
355
x
|
36.3
x
|
704
x
|
-
|
EV / Revenue
|
0.67
x
|
17.7
x
|
-571
x
|
-31.7
x
|
-1,103
x
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-1.12
x
|
0.54
x
|
80.4
x
|
68.4
x
|
-79.9
x
|
71.1
x
|
FCF Yield
|
-89.1%
|
185%
|
1.24%
|
1.46%
|
-1.25%
|
1.41%
|
Price to Book
|
0.74
x
|
1.5
x
|
2.5
x
|
5.22
x
|
5.37
x
|
1.98
x
|
Nbr of stocks (in thousands)
|
44,215
|
44,215
|
74,215
|
74,215
|
74,215
|
74,215
|
Reference price
2 |
0.2520
|
0.2060
|
0.2484
|
0.3425
|
0.2466
|
0.0936
|
Announcement Date
|
2/21/19
|
2/19/20
|
2/23/21
|
2/25/22
|
2/16/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
6.918
|
0.207
|
0.052
|
0.701
|
0.026
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
5.855
|
-0.973
|
-1.305
|
-0.469
|
-1.032
|
-1.044
|
Operating Margin
|
84.63%
|
-470.05%
|
-2,509.62%
|
-66.9%
|
-3,969.23%
|
-
|
Earnings before Tax (EBT)
1 |
5.855
|
-0.973
|
-1.304
|
-0.462
|
-0.386
|
1.217
|
Net income
1 |
5.849
|
-0.979
|
-1.311
|
-0.469
|
-0.186
|
1.373
|
Net margin
|
84.55%
|
-472.95%
|
-2,521.15%
|
-66.9%
|
-715.38%
|
-
|
EPS
2 |
0.1323
|
-0.0221
|
-0.0347
|
-0.0336
|
-0.0197
|
0.001320
|
Free Cash Flow
1 |
-4.138
|
6.791
|
-0.3696
|
-0.3251
|
0.359
|
-0.5635
|
FCF margin
|
-59.81%
|
3,280.62%
|
-710.82%
|
-46.38%
|
1,380.77%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/21/19
|
2/19/20
|
2/23/21
|
2/25/22
|
2/16/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
6.5
|
5.45
|
48.1
|
47.6
|
47
|
47
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-4.14
|
6.79
|
-0.37
|
-0.33
|
0.36
|
-0.56
|
ROE (net income / shareholders' equity)
|
48.5%
|
-9.3%
|
-4.87%
|
-0.99%
|
-0.4%
|
2.99%
|
ROA (Net income/ Total Assets)
|
29.2%
|
-5.53%
|
-2.98%
|
-0.61%
|
-1.35%
|
-1.37%
|
Assets
1 |
20
|
17.7
|
43.97
|
76.8
|
13.75
|
-100.3
|
Book Value Per Share
2 |
0.3400
|
0.1400
|
0.1000
|
0.0700
|
0.0500
|
0.0500
|
Cash Flow per Share
2 |
0.1500
|
0.1200
|
0.6500
|
0.6400
|
0.6300
|
0.6300
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/21/19
|
2/19/20
|
2/23/21
|
2/25/22
|
2/16/23
|
3/20/24
|
|
1st Jan change
|
Capi.
|
---|
| -3.85% | 6.68M | | +7.52% | 111B | | +11.38% | 106B | | -12.64% | 22.24B | | +0.44% | 21.25B | | -4.18% | 18.97B | | -37.85% | 18.52B | | -8.58% | 16.81B | | +37.41% | 12.54B | | -23.95% | 8.09B |
Bio Therapeutic Drugs
|